Background: Chronic constipation (CC) is a common and severe gastrointestinal complaint in Parkinson's disease (PD), but its pathogenesis remains poorly understood. This study evaluated functionally distinct submucosal neurons in relation to colonic motility and anorectal function in PD patients with constipation (PD/CC) vs both CC and controls.
subset (~10%) of patients develops symptoms before 50 years of age. 1 The pathological hallmarks of PD are a progressive degeneration of the dopamine-containing neurons in the substantia nigra pars compacta along with intraneuronal aggregates of eosinophilic inclusions (mainly phosphorylated α-synuclein), i.e. Lewy bodies (LBs) and Lewy neurites (LNs). 2 Although PD is regarded as a prototypical movement disorder, non-motor manifestations, such as autonomic dysfunctions, particularly those involving the gastrointestinal (GI) tract, are increasingly recognized as being a major aspect of the PD clinical picture. 3 Virtually all parkinsonian patients experience GI dysfunctions, such as dysphagia, delayed gastric emptying (up to gastroparesis), and severe chronic constipation (CC). 4, 5 Specifically, CC is a dominant manifestation in up to 80% of PD patients, 4 and it occurs 2-4 times more frequently in PD compared with age-and sex-matched non-PD subjects. 6 Furthermore, the administration of L-Dopa, the most used drug to manage motor symptoms of PD patients, induces a prominent inhibitory action on GI motility, thus worsening the severity of CC. 7 However, a delayed colonic transit is observed in PD patients also independently of drug treatment. 8 The severe CC in parkinsonian patients is often unresponsive to first-line treatment (e.g. osmotic laxatives), and it may evolve to severe complications such as megacolon and intestinal pseudo-obstruction.
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The enteric nervous system (ENS) is a prime target of the pathological process of PD as indicated by autopsies of parkinsonian patients revealing the widespread presence of LBs and/or LNs in myenteric and submucosal neurons throughout the GI tract. 12, 13 Furthermore, fullthickness biopsies of patients with idiopathic CC undergoing colectomy for treatment-resistant, severe slow transit CC show changes in myenteric and submucosal neurons. 14 Taken together, these features support strongly the role of altered ENS function in patients with PD and CC. The recent demonstration that colonic mucosal biopsies including submucosal tissue with its ganglionated plexus can be obtained during colonoscopy provided an important tool to investigate changes in the ENS at the cellular and molecular level occurring in patients with PD and GI dysfunction.
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Thus, this study was designed to investigate and correlate functional and neuronal features in a cohort of PD/CC patients in comparison with non-parkinsonian CC and healthy controls. Our morphological analysis focused on enteric neurons of submucosal plexuses, which play a critical role in controlling secretomotor functions but also participate to motility regulation in the GI tract. Understanding the mechanisms underlying bowel dysfunction in PD patients would ultimately allow for a better knowledge of the management and treatment of CC in these patients.
| MATERIALS AND METHODS

| Patient recruitment
The study design included three groups of patients: n=29 PD/CC 
| GI functional assessment
Both colonic transit time (TT) (expressed as the number of radiologically detected intracolonic radiopaque markers after 5 days) and anorectal manometry (AM) were performed in any CC patients with or without PD based on standardized methods 20, 21 (see Supporting information for methodological details). The asymptomatic controls underwent colonoscopy (neither TT nor AM were assessed).
| Tissue collection
During colonoscopy, n=4 mucosal biopsies (including the submucosa)
were taken from the descending colon in each PD/CC, CC, and control subject. Biopsies were processed according to standard protocols (see
Supporting information).
Key Points
• Chronic constipation is usually a severe gastrointestinal dysfunction in patients with Parkinson's disease, but its pathogenesis remains poorly understood.
• Colonic motor and rectal sensory functions are impaired in most parkinsonian constipated patients. Compared with controls, they display a decreased number of submucosal secretomotor neurons containing VIP immunoreactivity accompanied by a reduced mRNA expression of VIP and VIP receptors.
• The identification of molecular targets underlying constipation in parkinsonian patients may pave the way to new therapeutic strategies.
| Immunohistochemistry and neuronal cell bodies quantification
Submucosal whole mounts were analyzed using previously vali- 
| RT-qPCR analysis
RT-qPCR was performed for each patient/subject on the total RNA extracted from one frozen biopsy (see Supporting information). The relative gene expression analysis evaluated the following genes: VIP, VIP receptor 1 (VIPR1), and VIP receptor 2 (VIPR2). Data were calculated with ΔΔC T method using 18S as a reference gene. 
| Statistical analysis
| RESULTS
Among PD/CC patients, n=17 (58%) completed the study; n=7 (24%) refused colonoscopy (although they underwent TT and AM testing), n=1 (3.5%) refused both TT and AM assessment (but that patient underwent colonoscopy), n=3 (10%) refused TT (they had colonoscopy and AM), and n=1 (3.5%) refused AM (but had colonoscopy and TT).
In the group of CC patients, n=9 (90%) underwent TT and AM, while n=1 performed only AM.
| Functional constipation assessment in PC/CC and CC
Evaluation of colonic TT and AM was performed in 24 and 27 PD/CC patients, respectively ( for the identification of four subgroups of patients: i) delayed TT and altered AM (65%); ii) delayed TT only (13%); iii) altered AM pattern only (13%); and iv) no functional impairment (9%) (Fig. 1A) .
Conversely, non-PD CC patients were subdivided in two groups only: i) delayed TT and altered AM (33%) and ii) delayed TT only (67%) (Fig. 1B) . However, there were no differences in the mean number of pellets found in PD/CC vs CC patients (12.4±7.78 vs 11.9±4.65; P=.28) (Fig. 1C ).
| Submucosal neuron count
In order to define possible differences existing in the number of neu- and controls, respectively; ANOVA test, P=.357) ( Fig. 2A-B ).
| Submucosal cholinergic and VIP containing neurons
Both cholinergic and VIP containing neurons are widely represented in the human colonic submucosal plexus. P=.770) (Fig. 2C-D) . In contrast, the percentage of HuC/D/VIP-IR neurons was significantly reduced in PD/CC (72±14.6%) vs controls (87±9.2%) (P=.007), while no differences were observed between PD/ CC vs CC (78±16.4%; P=.292) and between CC vs controls (P=.321) (Fig. 2E-F ).
| VIP and VIP receptor mRNA expression
The reduced number of VIP containing neurons in the absence of changes in the total number of HuC/D and cholinergic neurons suggests VIP downregulation. Therefore, we tested whether VIP and its receptors, VIPR1 and VIPR2, gene expression were altered in PD/CC, CC, and controls ( Fig. 3A-C) . Figure 3A 
P=.001).
Compared with controls, VIPR1 expression (Fig. 3B) 
P<.0001).
In patients with PD/CC and CC with slow transit, there was a reduction (although not significant, P=.07) in VIP mRNA levels in PD/CC vs CC. However, PD/CC with slow transit showed a significant decrease of VIPR1and VIPR2 mRNA expression (P=.014 and P=.002, respectively) vs CC with slow transit (Fig. 4A-C) . patients. In contrast, in the non-parkinsonian CC group, only 33% of patients showed combined slow TT and altered AM patterns, but a high proportion (67%) displayed slow transit. Overall, the two groups, PD/CC and CC, were comparable in terms of slow transit assessed by objective measurements. Our functional data on PD/CC extend previous studies evaluating constipated parkinsonian patients. 23, 24 In fact, Sakakibara et al. demonstrated that slow transit constipation was prevalent in PD/CC patients, while anorectal abnormalities were identified only in a small proportion of patients. 24 In contrast, Edwards et al. found anorectal manometric abnormalities in 77% of the PD/CC cases and slow transit only in 31%. In that study, the acute administration of apomorphine has been shown to improve dyssynergic defecation symptoms in a subset of patients with PD/CC, thus implying that a dopaminergic dysfunction is also responsible for dyssynergia. 23 The differences between our findings and those reported by Sakakibara et al. and Edwards et al. may be explained by the severity of PD per se and sample size, i.e. the number of patients enrolled in the two mentioned studies (approximately 50% less than the current study).
In addition, the heterogeneity of pathogenetic factors contributing to CC in PD (e.g. delayed transit vs sensory-motor abnormalities) also needs to be taken into consideration, and thus, different groups of patients might show differences in their GI abnormalities and symptoms. Taken together, both this study and previous data indicate that both a delayed TT and abnormal anorectal manometric patterns contribute to CC in PD patients. The origin of these abnormalities is quite complex and, to date, two mechanisms have been proposed: i) ENS changes mainly in the myenteric plexus associated with LBs and LNs with or without neuronal loss; 11, 25 and ii) an altered extrinsic nerve input to the lower gut, thereby affecting the colonic and anorectal sensory-motor function. 26 In the human colonic submucosa, using specific antibodies to phosphorylated α-synuclein, Lebouvier et al.
showed In our study, we used a recently established methodology of obtaining deep biopsies including the mucosa and submucosa during colonoscopy to obtain a submucosal preparation with the submucosal ganglia. 15 The submucosa contains secretomotor/vasomotor neurons innervating mucosa and vasculature. 29, 30 We have found that both The difference in the expression of VIP protein and mRNA may be explained by the difficulty in detecting peptides at the level of cell bodies, due to axonal transport and peptide release. 34 The reason(s) for the VIP downregulation remain(s) unknown. Given the crucial regulatory role exerted by VIP in gut physiology, it is reasonable to speculate that this peptide can be selectively targeted by PD.
When comparing the PD/CC and CC patients with slow transit, without taking into consideration the anorectal alteration, our data indicated a trend toward reduced VIP mRNA expression and a significant downregulation of VIPR1 and VIPR2 in slow transit PD/CC vs CC.
Overall, these findings suggest that downregulation of VIP and VIPR expression are more prominent in slow transit PD/CC than in slow transit CC. The observation that human submucosal neurons project to the muscle layers in addition to the mucosa 35 
40
In conclusion, our study provides evidence for a downregulation of the VIP system, in addition to sensory-motor colonic and rectal abnormalities in patients with PD/CC. VIP containing neurons represents a major subset of submucosal, mainly secretomotor, neurons, and thus, a decrease in VIP neurons, as well as VIPR1 and VIPR2, might lead to dysfunctional secretory processes. VIP is a major stimulant of fluid secretion, and thus, a reduced production of VIP is likely to result in reduced fluid secretion, which might account for the development or aggravation of CC in PD patients. Sensory-motor and secretory abnormalities are likely to represent two prominent mechanisms contributing to the pathogenesis of CC particularly in PD patients.
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